EUP ( EIMC United Pharma )...

EIMC United Pharma:

Introduction:

Since its establishment in 1992 EIMC adopted a clear, determined corporate strategy, supported by a long-term plan aimed to position the company as the main distributor and supplier of Cytotoxics, plasma derivatives and Intensive Care products to the Egyptian Market. This target has almost been achieved through dedicated work and cooperation with foreign suppliers known for their good experience and excellent reputation in the manufacturing of these vital products.
The fact that Cytotoxics and Intensive Care products need a special way of handling and manufacturing precautions, compounded by the commercial factors related to the high investments needed and consequently financial risks, all these factors made it not easy for pharmaceutical manufacturers in the developing countries to penetrate this area of industry, Egypt is no exception and the market suffered in many occasions of shortages of these vital products.
Market dynamics and the implementation of international trade agreements (GATT & TRIPS) made it a must for Egypt to plan and seriously act for self-sufficiency of these desperately needed products.

EUP Facility

Supported by its wealth of experience and good exposure to the international pharmaceutical market, EIMC have decided to take the initiative to build the first facility of its kind in the Middle East & Africa for the production of an integrated wide range of cost –effective, value adding Anticancer and intensive care products. For this purpose a joint venture Company EUP (Eimc United Pharmaceuticals) has been established in 2003.

Main shareholders were:

· EIMC (Egyptian International Medical Center)
The biggest Egyptian distributor of anticancer drugs in Egypt.
· KUP (Korea United Pharmaceuticals)
A dynamic Korean company specialized in the production of anticancer products exported to 35
Countries worldwide, its role is to provide the know- How needed for the manufacturing process.
· United Douglas, USA
An American Pharmaceutical Company to provide technical assistance and back up the R& D of
the facility.
EUP manufacturing facility, which is currently under construction and planned to start commercial scale production on the first quarter of 2006 has been designed with flexibility in mind to meet current needs and allows for future expansion. The production area has been equipped to handle several product types and formulations; the plant will first produce liquid sterile parenterals (vials & Ampoules), with future plans to install a freeze dryer for lyophilized forms. The facility comprises several laboratories fitted out with the latest equipment designed to support a state of- the –art production within the same building.
The facility has been designed and constructed to meet the F.D.A. requirements, and European G.M.P. guidelines which means that EUP can:
· Manufacture its own range of oncology and intensive care products.
· Provide contract manufacturing for anti-cancer drugs to third parties.
Through out the production and laboratory operations our focus on quality is absolute. Adherence to strict operating procedures designed to meet all quality objectives is mandatory.

for further information don't hesitate to contact EUP